- Home
- PAYC vs RPRX Comparison
PAYC vs RPRX Comparison
Compare PAYC & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PAYC
- RPRX
- Stock Information
- Founded
- PAYC 1998
- RPRX 1996
- Country
- PAYC United States
- RPRX United States
- Employees
- PAYC N/A
- RPRX N/A
- Industry
- PAYC Computer Software: Prepackaged Software
- RPRX Biotechnology: Pharmaceutical Preparations
- Sector
- PAYC Technology
- RPRX Health Care
- Exchange
- PAYC Nasdaq
- RPRX Nasdaq
- Market Cap
- PAYC 12.6B
- RPRX 14.2B
- IPO Year
- PAYC 2014
- RPRX 2020
- Fundamental
- Price
- PAYC $216.91
- RPRX $32.60
- Analyst Decision
- PAYC Hold
- RPRX Strong Buy
- Analyst Count
- PAYC 11
- RPRX 4
- Target Price
- PAYC $219.10
- RPRX $42.50
- AVG Volume (30 Days)
- PAYC 752.8K
- RPRX 5.5M
- Earning Date
- PAYC 04-30-2025
- RPRX 05-08-2025
- Dividend Yield
- PAYC 0.70%
- RPRX 2.71%
- EPS Growth
- PAYC 51.70
- RPRX N/A
- EPS
- PAYC 8.92
- RPRX 1.91
- Revenue
- PAYC $1,883,200,000.00
- RPRX $2,263,576,000.00
- Revenue This Year
- PAYC $9.76
- RPRX $31.56
- Revenue Next Year
- PAYC $9.72
- RPRX $5.94
- P/E Ratio
- PAYC $24.32
- RPRX $17.05
- Revenue Growth
- PAYC 11.19
- RPRX N/A
- 52 Week Low
- PAYC $139.50
- RPRX $24.05
- 52 Week High
- PAYC $242.74
- RPRX $34.20
- Technical
- Relative Strength Index (RSI)
- PAYC 52.36
- RPRX 54.58
- Support Level
- PAYC $213.11
- RPRX $32.02
- Resistance Level
- PAYC $221.74
- RPRX $32.31
- Average True Range (ATR)
- PAYC 10.35
- RPRX 0.97
- MACD
- PAYC 0.61
- RPRX 0.12
- Stochastic Oscillator
- PAYC 86.36
- RPRX 97.84
About PAYC Paycom Software Inc.
Paycom is a fast-growing provider of payroll and human capital management software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 19,500 clients as of 2023, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.